114645-18-0

Basic information

• Product Name: (S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE
• Synonyms: BOC-L-TYR(BZL)-CHN2;(S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE;N-ALPHA-TERT-BUTYLOXYCARBONYL-O-BENZYL-L-TYROSINE-DIAZOMETHANE;N-alpha-t-Butyloxycarbonyl-O-benzyl-L-tyrosine-diazomethane, (S)-3-Boc-amino-1-diazo-3-(4-benzyloxy)phenyl-2-butanone;(S)-tert-Butyl (2-(4-(benzyloxy)phenyl)-4-diazo-3-oxobutan-2-yl)carbaMate;(S)-tert-butyl (1-(4-(benzyloxy)phenyl)-4-diazo-3-oxobutan-2-yl)carbamate(WXG00288)
• CAS NO: 114645-18-0
• Molecular Formula: C₂₂H₂₅N₃O₄
• Molecular Weight: 395.45
• Mol File: 114645-18-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE(114645-18-0)
• EPA Substance Registry System: (S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE(114645-18-0)

Safety Data

• Hazardous Substances Data: 114645-18-0(Hazardous Substances Data)

Usage

General Description

(S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE is a chemical compound with a complex structure that includes a BOC-protected amino group, a diazo group, and a benzyl ether group. It is a potentially hazardous compound due to the presence of the diazo group, which is highly reactive and can undergo explosive decomposition under certain conditions. (S)-3-BOC-AMINO-1-DIAZO-3-(4'-BENZYLOXY)PHENYL-2-BUTANONE is commonly used in organic synthesis as a reagent for the introduction of the diazo group into other molecules, and it may also have applications in the field of medicinal chemistry. Due to its potential hazards, it should be handled with caution and proper safety measures in a controlled laboratory setting.

Upstream product

• 70-25-7 N-Methyl-N'-nitro-N-nitrosoguanidine 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 543-27-1 isobutyl chloroformate 
• 186581-53-3 diazomethane 
• 1026977-99-0 C₂₆H₃₃NO₇ 

Downstream Products

• 127106-65-4 4-(4-benzyloxy-phenyl)-3-tert-butoxycarbonylamino-butyric acid methyl ester 
• 162541-08-4 ((S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-1-{4-[2-(3-methyl-2-oxo-imidazolidin-1-yl)-ethoxy]-benzyl}-propyl)-carbamic acid tert-butyl ester 
• 162540-90-1 ((S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-1-{4-[2-(2-oxo-oxazolidin-3-yl)-ethoxy]-benzyl}-propyl)-carbamic acid tert-butyl ester 
• 162541-14-2 {(S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-1-[4-(2-dimethylcarbamoyloxy-ethoxy)-benzyl]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 
• 175233-61-1 Morpholine-4-carboxylic acid 4-[(S)-2-tert-butoxycarbonylamino-4-((S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-3-hydroxy-butyl]-benzyl ester 
• 162540-49-0 {(S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-1-[4-(2-imidazol-1-yl-ethoxy)-benzyl]-propyl}-carbamic acid tert-butyl ester 
• 162540-84-3 {(S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-1-[4-(2-oxo-2-piperidin-1-yl-ethoxy)-benzyl]-propyl}-carbamic acid tert-butyl ester 
• 162541-04-0 {(S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-1-[4-(2-hydroxy-2-methyl-propoxy)-benzyl]-propyl}-carbamic acid tert-butyl ester 
• 162539-58-4 [(S)-1-(4-Benzyloxy-benzyl)-3-((S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 162540-93-4 {4-[(S)-2-tert-Butoxycarbonylamino-4-((S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-3-hydroxy-butyl]-phenoxy}-acetic acid 
• 175417-50-2 {(S)-3-((S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-1-[4-(2-hydroxy-propoxy)-benzyl]-propyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

α- and β-Substituted phosphonate analogs of LPA as autotaxin inhibitors

Autotaxin (ATX) is an attractive pharmacological target due to its lysophospholipase D activity which leads to the production of lysophosphatidic acid (LPA). Blockage of ATX produced LPA by small molecules could be a potential anticancer chemotherapy. In our previous study, we have identified the two β-hydroxy phosphonate analogs of LPA (compounds f17 and f18) as ATX inhibitors. With this work, we investigated α- and β-substituted phosphonate analogs of LPA and evaluated them for ATX inhibitory activity. The stereochemistry of β-hydroxy phosphonates was also studied.

Retrocarbamate protease inhibitors

The invention discloses compounds of the formula STR1 are disclosed as HIV protease inhibitors.